SonoSite's new NanoMaxx ultrasound system receives FDA clearance

NewsGuard 100/100 Score

SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for the point-of-care, announced today that the company has received FDA 510(k) clearance for its new NanoMaxx™ ultrasound system and is commencing US customer deliveries. International deliveries began at the end of June.

Based on SonoSite’s 4th generation Turbo technology, the six pound NanoMaxx system is the latest addition to SonoSite’s suite of specialized products for point-of-care visualization in medicine. Complete with streamlined one button optimization technology, a touch screen user interface and SonoSite’s industry-leading 5-year warranty, the NanoMaxx system is ideal for both hospital and office markets and designed to provide healthcare professionals with improved patient safety practices, expanded workflow capabilities and exam room flexibility.

Among the first to take delivery of a system, the Queensland Ambulance Service in Australia, is integrating ultrasound into their rapid response vehicle. “Ultrasound is an essential tool for providing immediate diagnostics, improving patient safety and ultimately raising the standard of patient care,” said Stephen Rashford, MD, the department’s medical director. “With a hand-carried system, our department will be able to assess and diagnose patients at the scene of an accident, such as aggressively managing chest injuries, and for higher level trauma cases, pre-notify the hospital of a patient’s arrival to guarantee the availability of an operating room.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals breakthrough in non-invasive detection of endometrial cancer